Skip to main content

03-06-2020 | ASCO 2020 | Conference coverage | Video

Expert comment: The ADAURA results

Lecia Sequist explains why the phase 3 trial of adjuvant osimertinib in early-stage non-small-cell lung cancer could be practice changing (5:17).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits